Insmed (INSM) | Stock Overview & Key Data
Insmed Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $212.81 on December 2, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Revolution Medicines
RVMD
|
28.61B Large-cap | 7.79% | 9.89% | 61.68% | 102.61% | 102.56% | 279.08% | 524.98% | 353.09% | 443.52% | 443.52% | 443.52% |
|
Royalty Pharma plc
RPRX
|
29.43B Large-cap | -1.08% | 2.69% | 17.72% | 40.85% | 39.66% | 57.49% | 72.01% | 24.65% | 11.98% | 11.98% | 11.98% |
Ownership & Short Interest
Calculate Your Insmed Investment Returns
Long-Term Investment Performance Analysis
Insmed stock price in Jul 2016 was $11.06, A $1,000.00 lump sum investment in Insmed made 9 years ago would be worth approximately $8,811.93 today, representing a exceptional return of 781.19%. This translates to an annualized return (CAGR) of 24.56%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is INSM's 52-week high and low?
- In the last 52 weeks, Insmed reached a high of $212.75 (on December 2, 2025) and a low of $90.39 (on June 10, 2026).
- What is the market cap and P/E ratio for INSM?
- Curious about Insmed's size and valuation? Its market capitalization stands at 31.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is -22.40, and the forward P/E (looking ahead) is 188.19.
- Does INSM pay dividends? If so, what's the yield?
- As for dividends, Insmed isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Insmed's main competitors or similar companies to consider before investing?
When looking at Insmed, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Revolution Medicines
RVMD28.61B Healthcare Biotechnology 279.08% 524.98% Royalty Pharma plc
RPRX29.43B Healthcare Biotechnology 57.49% 72.01% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Insmed Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Insmed's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -249.28%, the Debt to Equity ratio from the most recent quarter is 101.43, and its Gross Profit Margin stands at 83.24%.
- What is the recent revenue and earnings growth for INSM?
- Looking at Insmed's growth, its revenue over the trailing twelve months (TTM) was $606M. Compared to the same quarter last year (YoY), quarterly revenue grew by 152.60%, and quarterly earnings saw a YoY growth of 152.62%.
- How much of INSM stock is held by insiders and institutions?
- Wondering who owns Insmed stock? Company insiders (like executives and directors) hold about 0.55% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.